Pfizer (NYSE:PFE) inks a multiyear agreement with Gilead Sciences (NASDAQ:GILD) to provide contract manufacturing services at its McPherson, KS facility to produce and supply COVID-19 antiviral Veklury (remdesivir).
CEO Albert Bourla says the action is part of the company’s five-point plan to commit resources to address the pandemic.
Financial terms are not disclosed.
PFE and GILD are both up 1% premarket on light volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.